In genetics, you shut things down to find out what they do. COVID-19 has done the same to us – Sherwood Park News

Alex Zimmer wakes up early when he wants to build a mutant. He needs to get to the lab before the lights come on. The lights are a signal. They tell the fish its time to breed.

Zimmer, a post-doctoral fellow at the University of Alberta, studies zebrafish. As creatures, they arent much to look at, zebrafish. Theyre a few centimetres long. They have tell-tale blue-black and white stripes. But theyre not striking. They dont jump through any hoops. Theyre just plain fish, said Marc Ekker, who studies zebrafish at the University of Ottawa. Theyre probably the cheapest fish you can buy.

What zebrafish do have going for them is that they mature very quickly and they breed in big numbers. A female zebrafish can produce 200 eggs in a week. Theyre also cheap to raise and store. And on a genetic level, theyre quite similar to humans.

Thats part of what makes them such ideal candidates for genetic research. On the outside, theyre small and wiggly. They smell like fish. They have gills and little fishy mouths. But strip them down to their genetic architecture and they arent that different from you and I.

Of course, there are sometimes slight differences, Ekker said. But very often its the same. Nature did not reinvent the wheel many times.

Zimmer builds zebrafish mutants, turning off their genes one by one, to study the uptake of salt in freshwater fish. Ekker has used them in his lab to isolate genes involved in childhood epilepsy and brain development. Others, all over the world, have used them to study everything from cell regeneration to cancer growth, drug toxicity and novel treatments for rare disease.

Nature did not reinvent the wheel many times

Zebrafish are whats known as a model species. Theyre one of four main models geneticists use to map out what role specific genes play in development.We just want to understand how you build an animal, said Norbert Perrimon, a professor of genetics at Harvard Medical School.

Most research labs tend to specialize in one species or another. Charles Boone, at the University of Toronto, is a yeast guy. Perrimon focuses on fruit flies. There are fish people. Theres the mouse community. But no matter the species, theyre all doing some variation on the same thing: knocking out genes to find out what they do.

Its a research principle called loss of function and it underpins almost everything we know about the working lives, mishaps and miracles of genes. In fact, if loss of function studies did not exist, I dont know what we would be left with, Perrimon said.

Its a simple idea at its core, if one that has had a massive impact on modern science. To find out what something does, you shut it off and see what happens. Thats what makes genetics the closest thing there is to a fairy tale science. Its all about imagining what life would be like if some tiny part of it were never there.

In flies, you can remove one gene and the wings wont grow. You take away another one you may lose the eye, Perrimon said.Depending on the study, scientists can shut off genes in living models or breed mutants where specific genes never work. They can knock out genes one at a time or in combination. They can program genes to shut down later, once an organism has matured. They can, with incredible precision, target one spot among thousands in a genome and flick it off like a light switch.

If loss of function studies did not exist, I dont know what we would be left with

That kind of aim wasnt always possible. The earliest loss of function experiments were more scattershot. They relied on x-rays or chemical mutagens that shut down genes almost at random. Back then, knocking out genes was like shooting a flock of ducks with a shotgun, said Stephanie Mohr, who teaches functional genetics at Harvard. Eventually over the years, we learned to exercise more and more control, she said.

Today, most labs work with a technology called CRISPR-Cas9. It acts like a set of genetic scissors, snipping the genome at a precise point and preventing the cell from healing itself. CRISPR has changed everything about gene editing. Today, instead of targeting the whole metaphorical flock, scientists can pick out a single feather on a single duck and pluck it out.Were doing stuff we couldnt even imagine seven years ago, Boone said. If God did exist, he would invent this for us.

Today, thanks to CRISPR, Boone can tell you which genes are essential for yeast to live (about 1,000 of them) and which ones it can survive without (the other 5,000). That ratio holds true for other species too. A lot of (zebrafish) genes dont seem to have a particular function, Zimmer said. You get rid of (them) and the biological system doesnt change.

That applies to humans too. You can shut off thousands of human genes, one at a time, and still have cellular life. Living things, in other words, can survive a tremendous amount of loss.

How that survival happens, though, is its own whole world of inquiry. In some cases, when one gene is shut down, others can compensate, weakening themselves. Other genes, if lost, can cripple or change the organism in grand or tiny ways. Some of the first loss of function experiments were on a fruit fly gene related to eye colour: turn it off, they found, and the flys eyes go from red to white. Still other genes, once shut down, remain a mystery. Its not clear what they did or why. Turn them off and the effect is there, but it remains unknown a phantom loss that lingers unseen, inside.

I first learned about loss of function two years ago at a lunch at the University of Toronto. I was sitting next to a PhD student who explained her research on the subject to me. I was so struck by the concept that I made a note of it in my phone. Loss of function: In science you learn what something does by shutting it down.

Ive been trying to write about loss of function ever since, but I struggled to find the right way in. It was only recently that it struck me: loss of function is the perfect metaphor for the last six months of our lives.

The COVID-19 pandemic has taken away so many things from so many people. It forced us all to build mutant versions of the ways we live. Through lockdowns and lost friends, closed schools, isolated care homes and lonely deaths, weve learned what we cant survive, what we can and at what cost. You shut things down to find out what they do. And we know now, in a way we never could before, what family means, what human touch, what friendships and jobs and the chance to say goodbye all mean.

You shut things down to find out what they do, and along the way you learn what parts of yourself, and of your world, you need to stay alive.

rwarnica@nationalpost.com

twitter.com/richardwarnica

Continue reading here:
In genetics, you shut things down to find out what they do. COVID-19 has done the same to us - Sherwood Park News

Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation – Endpoints News

When Jim Broderick launched Massachusetts-based Palleon Pharmaceuticals in 2015, he had an office in Cambridges Kendall Square, a bit of seed money, and a blank canvas.

He set out to innovate within a new space in immunology, and recruited scientific co-founders Carolyn Bertozzi, a Stanford professor, and Paul Crocker, a professor and the head of the cell signaling and immunology division at the University of Dundee, Scotland, to help him do it.

When you start a new company in biotech, you need to be in something thats new and big, and you need to have the worlds best scientists behind you, Broderick, who was the first entrepreneur-in-residence at GSKs venture arm SR One, toldEndpoints News.

On Wednesday, the five-year-old company announced the completion of a $100 million Series B round to develop its pipeline of glyco-immunology therapies. Its lead program in oncology, an enzymatic sialoglycan degrader, is expected to hit the clinic next year.

Glycan-mediated immune regulation presents an enormous opportunity for novel therapeutics to treat a range of diseases characterized by immune system dysfunction, including cancer and inflammatory diseases, the CEO announced in a statement. Before Palleon, Broderick co-founded three other biotechs, including Ra Pharmaceuticals.

According to Broderick, its been known since 1959 that tumors have different glycan structures on their surfaces. But nobody could figure out what the glycans were doing, he said.

The answer, he added, was hiding in plain sight. But nobody could see it, because we didnt really have the lens to view the immune system in this way that we now do. The tumors, he said, use evolved glycan structures to hide from immune system attacks. And so Palleon is working on using cell surface sugar molecules to modulate immune activity.

In addition to its EAGLE platform, which uses enzymatic sialoglycan degradation to overcome intractable biological redundancy and enable a pan-immune anti-tumor response, the company also has its HYDRA platform, which characterizes cancer patients by their tumor surface glycan profile to identify which patients are most likely to respond. Palleon says its developing a broad pipeline of candidates that target individual Siglecs and other glycan-sensing receptors, which may be useful against inflammatory diseases like autoimmunity and fibrosis.

The Series B, led by Matrix Capital Manaement, will help push that pipeline toward the clinic, Broderick said. Returning investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures, and new investor Surveyor Capital also chipped in.

Its just a whole other angle of immune regulation You couldnt see it before and now when you see it, there seems to be a lot of opportunity, Broderick said.

See the article here:
Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation - Endpoints News

Importance of exercise to boost the immune system – Excalibur Online

Sergiy Slipchenko | Sports Editor

Photo Credit: Mahdis Habibinia / Edited by: Bhabna Banerjee

Over the past decade exercise and physical activity have been related to various health benefitsimproved metabolic health and reducing age-related dysfunction are just some of the reported positive effects of exercise.

This field of study is called exercise immunology and the pandemic has shifted the focus on how exercise can help prevent contracting the infection, or help combat it once it is inside the body.

Exercise immunology has been gaining traction for the past three decades, but it exploded in popularity since the pandemic began as people flocked to the internet for answers on how to protect themselves.

The increased interest in this topic can be seen in the massive jump in sales of exercise equipmentdumbbells were nearly sold out all throughout North America.

Alongside the newfound enthusiasm for exercise came the question of its effectiveness against COVID-19. While many aspects of exercise immunology have been explored, a lot of focus has shifted to how significant physical activity is at boosting the immune system when confronted with the coronavirus.

Professor Richard J. Simpson from the University of Arizona wrote about how exercise can prevent viral infections: Each bout of exercise, particularly whole-body dynamic cardiorespiratory exercise, instantaneously mobilizes literally billions of immune cells, especially those cell types that are capable of carrying out effector functions such as the recognition and killing of virus-infected cells.

While exercise may not prevent us from becoming infected if exposed, it is likely that keeping active will boost our immune system to help minimize the effects of the virus, ameliorate our symptoms, expedite our recovery times.

In addition to combating viruses, exercise helps with the negative effects of isolation and confinement stress which affect how well your immune system can deal with infection.

Exercise should be coupled with stress management, regular sleep, healthy nutrition, and proper hygiene to improve resistance to infection.

However, an article published in the Journal of Sport and Health Science highlights several studies that show evidence that heavy exertion was associated with transient immune dysfunction, elevated inflammatory biomarkers, and increased risk of upper respiratory tract infections.

Exercise can have great effects on physical and mental health, however, it should be properly balanced. The World Health Organization recommends that adults should attempt to fit 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise into their weekly routine.

Simpson wrote: While exercise may not prevent us from becoming infected if exposed, it is likely that keeping active will boost our immune system to help minimize the deleterious effects of the virus, ameliorate our symptoms, expedite our recovery times and lower the likelihood that we can infect others with whom we come into contact.

Exercise is not a cure-all for the COVID-19 virus and infection is still likely if in contact with an infected person. Social distancing and all preventative measures should continuously be practiced.

View original post here:
Importance of exercise to boost the immune system - Excalibur Online

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune…

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced the closing of an $82 million Series A financing. The financing was co-led by Canaan Partners, Samsara BioCapital and The Column Group, with participation from other undisclosed investors. Synthekine was founded by K. Christopher Garcia, Ph.D., to leverage discoveries showing that cytokines can be tuned to enhance their therapeutic effects.

Synthekine combines strengths in immunology, structural insights on cytokines and multiple engineering technologies to create optimized therapeutics against new and validated cytokine targets for the treatment of cancer and autoimmune disorders. Proceeds from this Series A financing will be used to advance Synthekines lead therapeutic programs into clinical studies, expand its discovery pipeline and hone its proprietary cytokine engineering platforms. The company currently has two lead programs in IND-enabling development: STK-012, an engineered Interleukin-2 (IL-2) partial agonist for the treatment of cancer, and the combination of STK-009 and SYNCAR-001, an orthogonal IL-2 ligand and a CD-19 CAR-T-cell therapy being studied in combination.

Cytokines have a fundamental role in the immune system and represent an enormous opportunity for innovative therapeutics. However, most cytokines broadly activate a wide range of cells that can simultaneously stimulate and suppress the immune system, making drug development against these targets challenging, said Debanjan Ray, chief executive officer of Synthekine. Chris Garcia has shown, for a wide range of therapeutically important cytokines, that cytokine efficacy and toxicity can be decoupled through structure-based protein engineering. These findings mean that many cytokines previously thought to be unsuitable as therapeutics can be transformed into safe and effective drugs. In addition to our highly differentiated IL-2-based programs, we have assembled multiple best-in-class technologies and an accomplished team to develop cytokine therapeutics by engineering them at the molecular level to enhance their activity and selectivity.

Unlocking cytokine therapeutics through unique structural biology insights

Cytokines are small, soluble proteins that are powerful regulators of the immune system and can stimulate a wide range of immune cells, primarily driven by their binding and interaction with cell surface receptors. Most cytokines are pleiotropic, meaning that a given cytokine can exert a range of responses across multiple cell types. Pleiotropy has proven to be a significant obstacle in the development of cytokine therapeutics. Existing cytokine therapeutics, such as aldesleukin (Proleukin) and interferons, demonstrate meaningful efficacy in cancer and other diseases but are limited by significant side effects.

Synthekine has licensed several cytokine programs and platforms from Stanford University. Research conducted in the Garcia lab at Stanford led to insights into the interaction of cytokines and their receptors, allowing researchers to engineer modified cytokines to deliver selective activity to particular cell types of therapeutic interest, giving them the potential for optimized efficacy, a larger therapeutic window and improved safety for patients. This research has been responsible for determining the three-dimensional structures for many different cytokine/receptor complexes, including IL-1, IL-2, IL-4, IL-6, IL-13, IL-15, IL-17, IL-23 and the three different classes of interferons.

A deep preclinical pipeline and proprietary platform

Synthekine is advancing several preclinical programs and innovative platform technologies. These include:

A collaborative company formation effort and seasoned leadership team

The founding members of Synthekines board of directors include Tim Kutzkey, Ph.D., managing partner of The Column Group; Srinivas Akkaraju, Ph.D., founding partner of Samsara BioCapital; and Julie Grant, general partner at Canaan Partners. Synthekine has also appointed biopharma veteran Nils Lonberg as an independent member of its board of directors.

Synthekines executive team is led by Debanjan Ray as chief executive officer. Mr. Ray was previously chief financial officer and head of business development at CytomX Therapeutics, where he was responsible for leading financing efforts and securing multiple strategic collaborations with major pharmaceutical companies that generated more than $400 million in upfront payments and up to $4 billion in milestones. The executive team also includes Martin Oft, M.D., as chief development officer, Rob Kastelein, Ph.D., as head of therapeutic discovery and Gregory Yedinak as senior vice president of technical operations.

Synthekines scientific advisory board is led by its founder, K. Christopher Garcia, Ph.D., professor of molecular and cellular physiology and structural biology at Stanford University School of Medicine, a Howard Hughes Medical Institute (HHMI) investigator and a member of both the National Academy of Sciences and the National Academy of Medicine.

About Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system. For more information, visit http://www.synthekine.com.

View original post here:
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune...

CHMP Recommends Approval of Lilly’s Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis | Small Molecules | News…

DetailsCategory: Small MoleculesPublished on Sunday, 20 September 2020 11:23Hits: 231

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine

INDIANAPOLIS, IN, USA I Septemer 18, 2020 I Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

This opinion marks the first step toward European regulatory approval for baricitinib (marketed as OLUMIANT) for patients with AD. If approved, baricitinib would become the first JAK inhibitor indicated to help treat patients with AD. The CHMP opinion is now referred for action to the European Commission, which grants approval in the European Union. A final decision is expected from the European Commission in the next one-two months.

"Due to the limited treatment options currently available for adult patients with AD, we're excited to further explore baricitinib's potential benefit for patients,"said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines. "At Lilly, we aspire to elevate treatment standards for patients with dermatologic conditions. Today's CHMP opinion brings us closer to providing a new medicine for adults living with AD in Europe."

The positive opinion was based on Lilly's Phase 3 BREEZE-AD clinical development program for baricitinib evaluating the medicine's potential to treat AD including BREEZE-AD1 and BREEZE-AD2, monotherapy studies investigating the efficacy and safety of baricitinib in moderate to severe AD patients; BREEZE-AD4, a study evaluating the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD who have failed or who are intolerant to, or have contraindications to cyclosporine; and BREEZE-AD7, a study evaluating the efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate to severe AD.

"Patients living with AD face difficulties on a daily basis, and this CHMP opinion marks an important milestone in providing adult AD patients with a new potential treatment option," said Prof. Thomas Bieber, M.D., Ph.D., M.D.R.A., Professor of Dermatology and Allergy, University Hospital in Bonn, Germany.

OLUMIANT is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis (RA).

Lilly has exclusive worldwide development and commercialization rights for baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases under a license and collaboration agreement with Incyte.

Information on the previously approved EU OLUMIANT indication (Rheumatoid Arthritis) can be found here.

Indication and Usage for OLUMIANT (baricitinib) tablets (inthe United States) for RA patients

OLUMIANT(baricitinib) 2-mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.Limitation of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

About OLUMIANT

OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. for the treatment of adults with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the U.S. for patients with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.1There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.2OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.1OLUMIANT is approved in more than 70 countries. OLUMIANT is developed by Lilly under license from Incyte Corporation.

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.3 AD is a heterogeneous disease both biologically and clinically, but may be characterized by chronic symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.4,5 AD affects approximately one-three percent of adults worldwide.6

Moderate to severe AD is characterized by intense itching, resulting in visibly damaged skin.7 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.8

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

AboutEli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us atlilly.comandlilly.com/newsroom.

About IncyteIncyteis aWilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information onIncyte, please visit Incyte.com and follow @Incyte.

1 Olumiant Prescribing Information, 2020.2 Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.3 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.4Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.5 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.6 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.7 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.8 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

Refer to:Kristen Porter Basu; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-447-2199 (media)Kevin Hern; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-277-1838 (investors)Catalina Loveman; This email address is being protected from spambots. You need JavaScript enabled to view it.; +1-302-498-6171 (Incyte media)Michael Booth, DPhil; This email address is being protected from spambots. You need JavaScript enabled to view it.; +1-302-498-5914 (Incyte investors)

SOURCE: Eli Lilly

Link:
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis | Small Molecules | News...

Global Biochemical Diagnostic Reagent Market Insights and Forecast 2020 to 2025 – The Daily Chronicle

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

The Biochemical Diagnostic Reagent market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

It incorporates Biochemical Diagnostic Reagent market evolution study, involving the current scenario, growth rate (CAGR), and SWOT analysis. Important the study on Biochemical Diagnostic Reagent market takes a closer look at the top market performers and monitors the strategies that have enabled them to occupy a strong foothold in the market. Apart from this, the research brings to light real-time data about opportunities that will completely transform the trajectory of the business environment in the coming years to 2025. Some of the key players in the global Biochemical Diagnostic Reagent market is cccc

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ http://marketresearchbazaar.com/requestSample/61377

According to 99Strategy, the Global Biochemical Diagnostic Reagent Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Biochemical Diagnostic Reagent market, the market size and growth, as well as the major market participants.

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Key Regions

Asia Pacific

North America

Europe

South America

Middle East & Africa

Key Companies

Roche

Siemens Healthineers

Beckman Coulter

Randox

BioSino

Beijing Leadman Biochemistry

FosunPharma

Beijing Strong Biotechnologies

Dojindo Laboratories

Sysmex

KAINOS Laboratories

DAAN Gene

Key Product Type

Liquid Double Reagent

Dry Powder Double Reagent

Market by Application

Hospital

Clinic

Laboratory

Main Aspects covered in the Report

Overview of the Biochemical Diagnostic Reagent market including production, consumption, status & forecast and market growth

2016-2020 historical data and 2021-2026 market forecast

Geographical analysis including major countries

Overview the product type market including development

Overview the end-user market including development

Impact of Coronavirus on the Industry

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/61377

Major Point of TOC:

Chapter One: Biochemical Diagnostic Reagent Market Overview

Chapter Two: Biochemical Diagnostic Reagent Market Segment Analysis by Player

Chapter Three: Biochemical Diagnostic Reagent Market Segment Analysis by Type

Chapter Four: Biochemical Diagnostic Reagent Market Segment Analysis by Application

Chapter Five: Biochemical Diagnostic Reagent Market Segment Analysis by Sales Channel

Chapter Six: Biochemical Diagnostic Reagent Market Segment Analysis by Region

Chapter Seven: Profile of Leading Biochemical Diagnostic Reagent Players

Chapter Eight: Upstream and Downstream Analysis of Biochemical Diagnostic Reagent

Chapter Nine: Development Trend of Biochemical Diagnostic Reagent (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample//detail/61377

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter :https://twitter.com/BazaarMrb

Follows to Linkdin :https://www.linkedin.com/company/market-research-bazaar-vrrb/

Here is the original post:
Global Biochemical Diagnostic Reagent Market Insights and Forecast 2020 to 2025 - The Daily Chronicle

Increase In Frequency Of Product Innovations To Drive The Biochemistry Analyser Market From 2024 – The Daily Chronicle

Market Size US$ 4,700 Mnin 2024, Market Growth CAGR of 5.5%, Market Trends Growing prevalence ofHealthcare Industry

The clinical use of biochemistry analyzers in measurement solutions such as latex agglutination, ion-selective potentiometry, and colorimetric & photometric testing. In addition to this, accuracy of biochemistry analyzers in analyzing blood and urine samples has benefited pathology labs and diagnostic centers across the globe. Persistence Market Research predicts that the global demand for biochemistry analyzers will continue to soar on the grounds of such factors.

A recent report published by Persistence Market Research projects that by the end of 2024, the global market for biochemistry analyzers will reach US$ 4,625.3 Mn in terms of value.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/6451

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/6451

Key findings in the report cite that the use of chemistry analyzers spans from high-throughput clinical labs to point-of-care clinics, and its use for testing enzymes, electrolytes and proteins is gaining traction.

The report current values the globalbiochemistry analyzer marketat a little over US$ 3,000 Mn. During the forecast period, revenues generated through global sales of biochemistry analyzers are, thus, expected to soar at a steady CAGR of 5.5%.

Key Research Insights from the Report include:

The global market for biochemistry analyzers represents absolute $ opportunity of US$ 154.6 Mn in 2017 over 2016 and incremental opportunity of US$ 1,570.8 Mn between 2016 and 2024

Apart from clinical diagnostics, critical applications of biochemistry analyzers include drugs-of-abuse testing and diagnostic testing of patients metabolic functions

Access Full Report @ https://www.persistencemarketresearch.com/checkout/6451

Over 40% of biochemistry analyzers sold across the globe during the forecast period will be concentrated in North America

Demand for biochemistry analyzers is also expected to surge in Asia-Pacific, revenues from which will record steadfast growth at 6.1% CAGR

Leading manufacturers of biochemistry analyzers are developing multiplexing analyzers a cost-effective upgrade to existing product line

The report further reveals that fully-automated biochemistry analyzers will remain in great demand in the years to come. In 2017 and beyond, more than 85% of global biochemistry analyzer revenues will be accounted by sales of fully-automated biochemistry analyzers.

Moreover, clinical diagnostics will also remain the largest application of biochemistry analyzers throughout the forecast period. Revenues accounted by global sales of biochemistry analyzers in clinical diagnostics are anticipated to register speedy growth at 5.7% CAGR.

The report further identifies diagnostic centers as largest end-users of biochemistry analyzers in the world. On the other hand, rising number of point-of-care diagnostic labs instated in hospitals will render a key end-user of biochemistry analyzers. Together, hospitals and diagnostics centers will be responsible for procure over two-third of global biochemistry analyzers revenues through 2024.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Read the original here:
Increase In Frequency Of Product Innovations To Drive The Biochemistry Analyser Market From 2024 - The Daily Chronicle

Department of Energy Awards $1M to CU Denver-Led Team for Computational Biology – CU Denver News

The U.S. Department of Energy (DOE) announced $5 million in funding for six new research projects in computational biology, $1,049,639 of which goes to Chris Miller, associate professor in CU Denvers Department of Integrative Biology, and his collaboratorsFarnoush Banaei-Kashani from CU Denver, Kelly Wrighton from CSU, and Chris Henry from DOE.

Millers project, titled Finding the Missing Pieces: Filling Gaps that Impede the Translation of Omics Data into Models, seeks to develop novel computational biology approaches and software to better understand microbial genomes relevant to the environment. According to Miller, there are parallels to studying the human microbiome in many challenges we see todayclimate change, bioenergy-relevant systems, and more.

Take, for example, a freshwater wetland system in Ohio. Miller and his colleagues studied this model for years because microbes in the soil of freshwater wetlands naturally emit the greenhouse gas methane. All that said, we know relatively little about the controls on this microbial process or how changing climate or land-use practices might affect emissions.

There are thousands of different types of microbes (bacteria, fungi, etc.) living in even just a pinch of this soil, Miller said. But we have no clue how to grow and study most of them in the lab, so DNA sequencing and computation give us the ability to extract DNA directly from soil, sequence the bits of genome we recover, and then computationally try to piece the original genomes back together.

The reason this matters? Miller notes by following this process, we are able to actually predict which proteins those genomes encode and infer what the microbes might be doing in the environment.

In some of these complex soils, we are discovering novel organismslots of themand the genes we are sequencing often look nothing like scientists have characterized in the lab before, Miller said. New computational approaches are needed to infer microbial biochemistry and metabolism from the DNA so we can better understand and predict microbial roles in the larger ecosystems.

By developing new algorithms and software for analyzing microbial genomes recovered from the environment, Miller and his team will develop and scale new computational methods to infer functions for genes. This will be integrated into a DOE computational biology system called KBase so scientists all over the world can utilize their methods to more efficiently figure out what proteins and genomes are doing in their systems of interest.

This project is exciting because it is foundational to answering so many different kinds of questions, said Miller. Biology is increasingly Big Data science, and we need to make sure we have the computational tools to keep up with the data generation Our collaborators on this project are world-class, and I feel grateful that CU Denver students and I will have the chance to work with and learn from this team to advance the science.

Related Research: Genetic Adaptation to Climate Change Is Swift in Crop Pests

Awards were selected based on competitive peer review under a DOE Funding Opportunity Announcement issued by the Office of Biological and Environmental Research (BER) within DOEs Office of Science. Total funding is $5 million in Fiscal Year 2020 dollars, for projects up to three years in duration.

A list of projects can be found on the BER homepage under the heading, Whats New.

Continue reading here:
Department of Energy Awards $1M to CU Denver-Led Team for Computational Biology - CU Denver News

Recruiting Faculty in Molecular and Cellular Biology – Nature.com

We invite applications for faculty at the levels of Assistant and Associate Professor within the Department of Molecular and Cellular Biology at Baylor College of Medicine (BCM). BCM is located within the Texas Medical Center in Houston, a premier research and clinical environment.

We are seeking motivated investigators in broad areas of normal and cancer biology, including but not limited to gene regulation, epigenetics, and synthetic biology. BCM offers competitive startup packages and our researchers are supported by outstanding core facilities providing access to dedicated expertise in Genomic, Transcriptomic, and Proteomic Profiling, Advanced and Vital Microscopy, Flow Cytometry, Stem Cell Culture, Live Bioimaging, Metabolomics, and more.

Our Department offers a collegial, collaborative environment and maintains a long-standing tradition of strong support for new faculty. Recruited faculty have the opportunity to join as members of the NCI-designated Dan L Duncan Comprehensive Cancer Center.

BCM is located in the heart of the Texas Medical Center in Houston and is affiliated with surrounding educational institutions, including the University of Texas Medical School, the UT MD Anderson Cancer Center, and Rice University.

Applications received by November 1, 2020 will receive priority.

Please send a cover letter, a CV and a 2-4 page summary of research interests to:

MCB_communications@bcm.edu.

Baylor College of Medicine is an Equal Opportunity/Affirmative Action/Equal Access Employer

Excerpt from:
Recruiting Faculty in Molecular and Cellular Biology - Nature.com

Enhancing the efficacy of anti-PD-L1 immunotherapy for cancer – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Sep 18 2020

For most people, there is no scarier diagnosis than that of cancer. While treatments including chemotherapy and radiotherapy have been used since the 1940s and late 1800s, respectively, immunotherapy has more recently emerged as a viable and successful approach to cancer treatment. Indeed, evasion of the host immune system is an essential feature of tumorigenesis. Figuring out how cells do this, and disrupting it, to allow the patient's own immune system to eliminate the cancer cells, is the basis of immunotherapy.

In a study published in August 2020 in Nature Cell Biology, a team including researchers from Tokyo Medical and Dental University (TMDU) and Harvard Medical School (HMS) have identified the regulatory mechanisms through which the PD-L1 immune check-point protein dictates the efficacy of anti-PD-L1 immunotherapy.

We already knew that immunotherapies targeting immune-checkpoint inhibitors were somewhat successful in treating some cancer types. However, only a subset of patients achieved long-lasting results."

Naoe Taira Nihira, Co-Author

PD-L1 expression is tightly controlled, and patients with increased PD-L1 expression in tumors are likely to respond well to PD-L1 blockade; however, the reasons why increased PD-L1 expression leads to increased PD-L1 blockade sensitivity have remained unclear. The research team examined a specific kind of PD-L1 modification, called acetylation, and found that removal of this modification allows PD-L1 to enter the nucleus and interact with DNA to regulate the immune response.

Using a variety of advanced molecular, biochemical, and bioinformatics approaches, the researchers examined PD-L1 acetylation, localization, function, and interactions. They found that plasma membrane localized PD-L1 translocates to the nucleus by interacting with transport pathway components. Specifically, by introducing a series of mutations into PD-L1 and expressing different acetyltransferases, they determined that PD-L1 is acetylated by p300 at a specific residue within the cytoplasm called Lys263. Using similar approaches, and protein depletion by short-interfering RNAs, they also discovered that histone deacetylase (HDAC) specifically interacts with and deacetylates PD-L1.

Protein modifications, including acetylation, can affect protein stability, dimerization, or localization. However, when the team reduced the amount of HDAC2 protein in the cells, consequently increasing the acetylation level, there were no observable changes in protein stability or dimerization. Co-author Akira Nakanishi explains: "These results mean that the acetylation and deacetylation of PD-L1 at this residue play a critical role in its nuclear translocation."

In the nucleus, PD-L1 regulates the expression of pro-inflammatory and immune-response-related genes, indicating that PD-L1 could function to regulate the local tumor immune environment to control its sensitivity to immune checkpoint-blockade therapy .

Given the health and economic burdens of cancer worldwide, new treatment approaches with increased efficacy are continually being sought. The results presented by this team indicate that targeting PD-L1 translocation can be used to enhance the efficacy of PD-1/PD-L1 blockade-based immunotherapy approaches.

Source:

Journal reference:

Gao, Y., et al. (2020) Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology. doi.org/10.1038/s41556-020-0562-4.

Here is the original post:
Enhancing the efficacy of anti-PD-L1 immunotherapy for cancer - News-Medical.net